NCT05838521: An ongoing trial by Yale University
This trial is ongoing. It must report results 1 year, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05838521 |
|---|---|
| Title | A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 2, 2023 |
| Completion date | June 1, 2026 |
| Required reporting date | June 1, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |